COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN COLOMBIA

被引：1
|
作者：
Nunez, S. M. [1 ]
Mould-Quevedo, J. F. [2 ]
Gutierrez-Ardila, M., V [1 ]
Roberts, C. S. [2 ]
La Rotta, J. E. [1 ]
机构：
[1] Pfizer Colombia, Bogota, Cundinamarca, Colombia
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1304
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A242 / A242
页数：1
相关论文
共 50 条
  • [41] 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study (vol 62, pg 1427, 2015)
    De Montalembert, M.
    Abboud, M. R.
    Fiquet, A.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (02)
  • [42] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Rajeev Dhere
    Vistasp Sethna
    Hitesh Malviya
    Rajeshwari Adhiseshan
    Infectious Diseases and Therapy, 2022, 11 : 1297 - 1299
  • [43] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Johnna Perdrizet
    Emily K. Horn
    Winniefer Nua
    Judith Perez-Peralta
    Jennifer Nailes
    Jaime Santos
    Anna Ong-Lim
    Infectious Diseases and Therapy, 2021, 10 : 2625 - 2642
  • [44] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Dhere, Rajeev
    Sethna, Vistasp
    Malviya, Hitesh
    Adhiseshan, Rajeshwari
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (03) : 1297 - 1299
  • [45] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [46] Prognoses of patients undergoing hemodialysis administered 23-valent pneumococcal polysaccharide versus 13-valent pneumococcal protein conjugate vaccines
    Yamaguchi, Kosei
    Kitamura, Mineaki
    Takazono, Takahiro
    Hashiguchi, Junichiroh
    Funakoshi, Satoshi
    Mukae, Hiroshi
    Nishino, Tomoya
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (12) : 1126 - 1131
  • [47] Impact of PCV13 and PPSV23 Vaccination on Invasive Pneumococcal Disease in Adults with Treated Rheumatoid Arthritis: A Population-Based Study
    Alvarez, Carlos A.
    Hall II, Ronald G.
    Lin, Suzy
    Perkins, Aaron R.
    Mortensen, Eric M.
    MICROORGANISMS, 2024, 12 (10)
  • [48] Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients
    Nils Mülling
    Lukas van de Sand
    Kim Völk
    Ulrich Wilhelm Aufderhorst
    Mark van der Linden
    Peter A. Horn
    Andreas Kribben
    Benjamin Wilde
    Adalbert Krawczyk
    Oliver Witzke
    Monika Lindemann
    Infection, 2023, 51 : 1703 - 1716
  • [49] Evaluation of appropriateness of vaccination procedures of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in a hospital setting
    Coleman, Paige
    Sears, Matthew
    Vaichys, Sabina
    Nemecek, Branden
    Guarascio, Anthony
    PHARMACOTHERAPY, 2015, 35 (11): : E305 - E305
  • [50] Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
    Perdrizet, Johnna
    Santana, Carlos Felipe S.
    Senna, Thais
    Alexandre, Rodrigo Fernandes
    de Almeida, Rodrigo Sini
    Spinardi, Julia
    Wasserman, Matt
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) : 1162 - 1172
12345